Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Baxter
Medtronic
Merck
Mallinckrodt

Last Updated: January 29, 2022

DrugPatentWatch Database Preview

Claims for Patent: 8,241,849

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 8,241,849
Title:Isolated genomic polynucleotide fragments that encode human lipoprotein-associated phospholipase A2
Abstract: The invention is directed to isolated genomic polynucleotide fragments that encode human lipoprotein-associated phospholipase A2, vectors and hosts containing the fragment and fragments hybridizing to noncoding regions as well as antisense oligonucleotides to these fragments. The invention is further directed to methods of using these fragments to obtain human lipoprotein-associated phospholipase A2 and to diagnose, treat, prevent and/or ameliorate a pathological disorder.
Inventor(s): Ryan; James W (Augusta, GA)
Assignee: Ryogen LLC (Suffern, NY)
Application Number:12/323,364
Patent Claims:1. A method of detecting the presence or absence of a polynucleotide in a sample, said polynucleotide selected from the group consisting of: (i) a polynucleotide which is at least 99% identical to the polynucleotide of SEQ ID NO:2, which encodes a polypeptide which is at least 99% identical to the amino acid sequence of SEQ ID NO:1, wherein said polypeptide has human lipoprotein-associated phospholipase A2 activity; (ii) a fragment of (i) comprising at least nucleotides 11967-30301, which encodes a polypeptide which is at least 99% identical to the amino acid sequence of SEQ ID NO:1, wherein said polypeptide has lipoprotein-associated phospholipase A2 activity; and (c) the full complement of (i) or (ii), said method comprising (a) contacting the sample with an isolated polynucleotide probe or primer, wherein said probe or primer is a fragment of a polynucleotide which is at least 99% identical to SEQ ID NO:2 and wherein said polynucleotide probe or primer comprises at least 20 contiguous nucleotides of SEQ ID NO:2 or its full complement which contains a transcription factor binding site at an NFAT_Q6 site at nucleotides 11523-11541, and (b) determining whether the polynucleotide probe or primer binds to a polynucleotide sequence in the sample, wherein binding of a polynucleotide of the sample to said probe or primer in step (a) detects the presence of a polynucleotide comprising SEQ ID NO:2.

2. The method according to claim 1, wherein said sample is contacted with a probe between 50-2000 contiguous nucleotides in length.

3. A method for detecting the presence of a polynucleotide in a sample, said polynucleotide selected from the group consisting of: (i) a polynucleotide which is at least 99% identical to the polynucleotide of SEQ ID NO:2; (ii) a fragment of (i) comprising at least nucleotides 11967-30301 of SEQ ID NO:2, and (iii) the full complement of (i) or (ii) in a sample, comprising (a) contacting the sample with a polynucleotide probe or primer comprising the 5'-noncoding region, 3'-noncoding region or intron region of SEQ ID NO:2 or its complementary sequence and (b) determining whether the polynucleotide probe or primer binds to said nucleic acid molecule in the sample.

4. The method according to claim 3, wherein the polynucleotide or probe comprises the intron region of SEQ ID NO:2 or its complementary sequence.

5. The method according to claim 1, wherein the polynucleotide or probe is a DNA or RNA sequence.

6. The method according to claim 3, wherein the polynucleotide or probe is a DNA or RNA sequence.

Details for Patent 8,241,849

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 1986-06-04 ⤷  Try it Free 2021-05-30
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try it Free 2021-05-30
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Mallinckrodt
Moodys
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.